Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trial
Bitopertin significantly reduced protoporphyrin-IX levels, showed improved measures of sunlight tolerance, and had a favorable safety profile in patients with erythropoietic protoporphyria.
Authors
- Manisha Balwani (ORCID: https://orcid.org/0000-0001-8047-5011)
- Will Savage
- Amy K. Dickey (ORCID: https://orcid.org/0000-0003-2979-9664)
- Melanie Chin (ORCID: https://orcid.org/0000-0002-2771-0518)
- Cynthia Levy (ORCID: https://orcid.org/0000-0001-5498-6037)
- Manish Thapar (ORCID: https://orcid.org/0000-0003-2729-4507)
- Karl E. Anderson (ORCID: https://orcid.org/0000-0002-6499-8573)
- Robert J. Desnick (ORCID: https://orcid.org/0000-0001-5501-2971)
- Sioḃán Keel (ORCID: https://orcid.org/0000-0002-9599-8226)
- Bruce Wang
- Herbert L. Bonkovsky
Institutions
- Atrium Health Wake Forest Baptist (US)
- Harvard University (US)
- University of Miami (US)
- University of California, San Francisco (US)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
- United Electric Controls (United States) (US)
- 480 Biomedical (United States) (US)
- Temple University Hospital (US)
- Desert Institute For Spine Care (US)
- The University of Texas Medical Branch at Galveston (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1016/j.jaad.2025.12.024
- Citations
- 2
- Primary Topic
- Porphyrin Metabolism and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.61